Indo Borax & Chemicals Q1FY27 net profit surges 62% to ₹162.5 crore
Indo Borax & Chemicals posted strong Q1FY27 results with net profit jumping 62% to ₹162.5 crore on robust revenue growth and improved margins. The Board also approved the amalgamation of its subsidiary Indoborax Infrastructure Private Limited.

*this image is generated using AI for illustrative purposes only.
Indo Borax & Chemicals reported a significant improvement in its financial performance for the quarter ended June 30, 2026, with standalone net profit rising 62% year-on-year to ₹162.5 crore. The growth was primarily driven by a 31% increase in revenue from operations to ₹703.6 crore and an expansion in EBITDA margins, reflecting strong operational efficiency and demand for its chemical products.
The Board of Directors, at its meeting held on August 10, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Bohra & Co., pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the Board approved a draft Postal Ballot Notice to seek shareholders' approval for proposed resolutions, which will be dispatched in due course.
Strong Revenue and Margin Expansion
Indo Borax & Chemicals' revenue from operations increased to ₹703.6 crore in Q1FY27 from ₹535.7 crore in the corresponding quarter of the previous year. This top-line growth was accompanied by a substantial improvement in profitability metrics. The company's profit from operations before exceptional items and tax (EBITDA) rose to ₹220.0 crore from ₹141.5 crore YoY. Consequently, the EBITDA margin expanded significantly, indicating better cost management and operational leverage during the period.
The following table summarises the key financial metrics for the quarter on a year-on-year basis:
| Metric: | Q1FY27 | Q1FY26 (YoY) |
|---|---|---|
| Revenue from Operations: | ₹703.6 crore | ₹535.7 crore |
| Profit from Operations (EBITDA): | ₹220.0 crore | ₹141.5 crore |
| Net Profit (Standalone): | ₹162.5 crore | ₹100.4 crore |
| EPS (Basic & Diluted): | ₹5.07 | ₹3.13 |
Bottom Line Reflects Operational Strength
The standalone net profit for the quarter stood at ₹162.5 crore, compared to ₹100.4 crore in Q1FY26. This 62% jump in bottom-line performance underscores the company's ability to translate higher revenues into stronger profits. The earnings per share (EPS) also increased to ₹5.07 from ₹3.13 in the year-ago quarter. Consolidated net profit mirrored this trend, rising to ₹162.5 crore from ₹102.0 crore YoY.
What the Numbers Show
The divergence between revenue growth (31%) and EBITDA growth (55%) highlights a notable improvement in operating margins. This margin expansion suggests that Indo Borax & Chemicals is benefiting from either favorable product mix pricing or effective control over input costs. With total comprehensive income reaching ₹184.8 crore, the company demonstrates robust overall financial health, supported by stable other comprehensive income components.
Corporate Developments
In addition to the financial results, the Board approved the Scheme of Amalgamation of its wholly-owned subsidiary, Indoborax Infrastructure Private Limited, with the parent company. This scheme is subject to requisite statutory and regulatory approvals, including those from the National Company Law Tribunal (NCLT). The amalgamation aims to streamline operations and enhance governance efficiency within the group structure.
Historical Stock Returns for Indo Borax & Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +7.17% | +14.46% | +4.72% | +76.53% | +55.61% | +190.13% |
Will the margin expansion driven by favorable product mix and cost control be sustainable in Q2FY27, or is it likely to normalize as input costs fluctuate?
How might the proposed amalgamation of Indoborax Infrastructure Private Limited impact the company's capital structure and operational overheads once NCLT approval is secured?
What specific regulatory or market factors are driving the 31% revenue growth, and are these tailwinds expected to persist for the remainder of FY27?


































